DESTINY-Biliary Tract Cancer-01: A phase 3 study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus standard-of-care Gemcitabine, Cisplatin, and Durvalumab for first line locally advanced or metastatic HER2-expressing biliary tract cancer

MyChart

Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
Request an Appointment

If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information

New Patients Current Patients Referring Physicians
Donate Today